ESE-1 is a Novel Transcriptional Mediator of Angiopoietin-1 Expression in the Setting of Inflammation
Courtney Brown,John Gaspar,Allison Pettit,Rebecca Lee,Xuesong Gu,Hong Wang,Cathy Manning,Carole Voland,Steven R. Goldring,Mary B. Goldring,Towia A. Libermann,Ellen M. Gravallese,Peter Oettgen
DOI: https://doi.org/10.1074/jbc.m308593200
IF: 5.485
2004-01-01
Journal of Biological Chemistry
Abstract:Angiogenesis is a critical component of the inflammatory response associated with a number of conditions. Angiopoietin-1 (Ang-1) is an angiogenic growth factor that promotes the chemotaxis of endothelial cells and facilitates the maturation of new blood vessels. Ang-1 expression is up-regulated in response to tumor necrosis factor-α (TNF-α). To begin to elucidate the underlying molecular mechanisms by which Ang-1 gene expression is regulated during inflammation, we isolated 3.2 kb of the Ang-1 promoter that contain regulatory elements sufficient to mediate induction of the promoter in response to TNF-α, interleukin-1β, and endotoxin. Surprisingly, sequence analysis of this promoter failed to reveal binding sites for transcription factors that are frequently associated with mediating inflammatory responses, such as NF-κB, STAT, NFAT, or C/EBP. However, putative binding sites for ETS and AP-1 transcription factor family members were identified. Interestingly, among a panel of ETS factors tested in a transient transfection assay, only the ETS factor ESE-1 was capable of transactivating the Ang-1 promoter. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are functionally important for transactivation by ESE-1. ESE-1 and Ang-1 are induced in synovial fibroblasts in response to inflammatory cytokines, with ESE-1 induction slightly preceding that of Ang-1. Mutation of a high-affinity ESE-1 binding site leads to a marked reduction in Ang-1 transactivation by ESE-1, inducibility by inflammatory cytokines, and DNA binding to the ESE-1 protein. Transcriptional profiling of cells transiently transfected with an ESE-1 expression vector demonstrates that the endogenous Ang-1 gene is directly inducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a similar and strong expression pattern in the synovium of patients with rheumatoid arthritis. Our results support a novel paradigm for the ETS factor ESE-1 as a transcriptional mediator of angiogenesis in the setting of inflammation. Angiogenesis is a critical component of the inflammatory response associated with a number of conditions. Angiopoietin-1 (Ang-1) is an angiogenic growth factor that promotes the chemotaxis of endothelial cells and facilitates the maturation of new blood vessels. Ang-1 expression is up-regulated in response to tumor necrosis factor-α (TNF-α). To begin to elucidate the underlying molecular mechanisms by which Ang-1 gene expression is regulated during inflammation, we isolated 3.2 kb of the Ang-1 promoter that contain regulatory elements sufficient to mediate induction of the promoter in response to TNF-α, interleukin-1β, and endotoxin. Surprisingly, sequence analysis of this promoter failed to reveal binding sites for transcription factors that are frequently associated with mediating inflammatory responses, such as NF-κB, STAT, NFAT, or C/EBP. However, putative binding sites for ETS and AP-1 transcription factor family members were identified. Interestingly, among a panel of ETS factors tested in a transient transfection assay, only the ETS factor ESE-1 was capable of transactivating the Ang-1 promoter. ESE-1 binds to specific ETS sites within the Ang-1 promoter that are functionally important for transactivation by ESE-1. ESE-1 and Ang-1 are induced in synovial fibroblasts in response to inflammatory cytokines, with ESE-1 induction slightly preceding that of Ang-1. Mutation of a high-affinity ESE-1 binding site leads to a marked reduction in Ang-1 transactivation by ESE-1, inducibility by inflammatory cytokines, and DNA binding to the ESE-1 protein. Transcriptional profiling of cells transiently transfected with an ESE-1 expression vector demonstrates that the endogenous Ang-1 gene is directly inducible by ESE-1. Finally, Ang-1 and ESE-1 exhibit a similar and strong expression pattern in the synovium of patients with rheumatoid arthritis. Our results support a novel paradigm for the ETS factor ESE-1 as a transcriptional mediator of angiogenesis in the setting of inflammation. Inflammation is an important component of several pathological conditions, including wound healing, atherosclerosis, and arthritis. Inflammation is often associated with the development of granulation tissue consisting of infiltrating mononuclear cells and blood vessels (1Jackson J.R. Seed M.P. Kircher C.H. Willoughby D.A. Winkler J.D. Faseb J. 1997; 11: 457-465Crossref PubMed Scopus (611) Google Scholar, 2Koch A.E. Harlow L.A. Haines G.K. Amento E.P. Unemori E.N. Wong W.L. Pope R.M. Ferrara N. J. Immunol. 1994; 152: 4149-4156PubMed Google Scholar). As this tissue proliferates there are zones of relative hypoxia where growth of the tissue has outstripped the blood vessel supply, triggering signals for further blood vessel development (3Walsh D.A. Rheumatology (Oxford). 1999; 38: 103-112Crossref PubMed Scopus (210) Google Scholar). The angiogenesis that results from these signals provides the necessary blood supply, oxygen, and nutrients to support the proliferating tissue, and plays an active role in the transport of inflammatory cells to the site of inflammation (4Koch A.E. Arthritis Rheum. 1998; 41: 951-962Crossref PubMed Scopus (434) Google Scholar). The endothelial cells themselves also provide a source of proinflammatory cytokines.One of the first steps in this process is the induction of angiogenic growth factors such as basic fibroblast growth factor (bFGF) 1The abbreviations used are: bFGF, basic fibroblast growth factor; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; VEGF, vascular endothelial growth factor; Ang-1, angiopoietin-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RA, rheumatoid arthritis; TNF, tumor necrosis factor; RT, reverse transcriptase; TBS, Tris-buffered saline. 1The abbreviations used are: bFGF, basic fibroblast growth factor; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; VEGF, vascular endothelial growth factor; Ang-1, angiopoietin-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RA, rheumatoid arthritis; TNF, tumor necrosis factor; RT, reverse transcriptase; TBS, Tris-buffered saline. and vascular endothelial growth factor (VEGF) (5Senger D.R. Claffey K.P. Benes J.E. Perruzzi C.A. Sergiou A.P. Detmar M. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 13612-13617Crossref PubMed Scopus (454) Google Scholar). These growth factors promote the proliferation and migration of endothelial cells to sites of inflammation, which is facilitated by the expression of matrix degrading enzymes and integrins on activated endothelial cells (6Senger D.R. Ledbetter S.R. Claffey K.P. Papadopoulos-Sergiou A. Peruzzi C.A. Detmar M. Am. J. Pathol. 1996; 149: 293-305PubMed Google Scholar). Endothelial cells that have migrated to sites of inflammation then organize into small tubes. The formation of stable blood vessels requires the recruitment of surrounding mesenchymal cells and their differentiation into vascular smooth muscle cells. Vessel maturation is facilitated by the angiopoietins (7Suri C. Jones P.F. Patan S. Bartunkova S. Maisonpierre P.C. Davis S. Sato T.N. Yancopoulos G.D. Cell. 1996; 87: 1171-1180Abstract Full Text Full Text PDF PubMed Scopus (2371) Google Scholar).Ang-1 has the unique property of enhancing the stability of new blood vessels by recruiting surrounding mesenchymal cells and promoting their differentiation to vascular smooth muscle cells (7Suri C. Jones P.F. Patan S. Bartunkova S. Maisonpierre P.C. Davis S. Sato T.N. Yancopoulos G.D. Cell. 1996; 87: 1171-1180Abstract Full Text Full Text PDF PubMed Scopus (2371) Google Scholar). In contrast to other angiogenic substances like VEGF or bFGF, Ang-1 is not a potent mitogen for endothelial growth. However, Ang-1 is a potent chemoattractant of endothelial cells and enhances endothelial cell migration. Other properties of Ang-1 include its ability to promote the adhesion of endothelial cells to fibronectin, as well as its ability to prevent endothelial cell death by inhibiting apoptosis (8Huang X.L. Takakura N. Suda T. Biochem. Biophys. Res. Commun. 1999; 264: 133-138Crossref PubMed Scopus (29) Google Scholar, 9Fujikawa K. de Aos Scherpenseel I. Jain S.K. Presman E. Varticovski L. Exp. Cell Res. 1999; 253: 663-672Crossref PubMed Scopus (125) Google Scholar).We and others (10Gravallese E.M. Pettit A.R. Lee R. Madore R. Manning C. Tsay A. Gaspar J. Goldring M.B. Goldring S.R. Oettgen P. Ann. Rheum. Dis. 2003; 62: 100-107Crossref PubMed Scopus (80) Google Scholar, 11Scott B.B. Zaratin P.F. Colombo A. Hansbury M.J. Winkler J.D. Jackson J.R. J. Rheumatol. 2002; 29: 230-239PubMed Google Scholar, 12Shahrara S. Volin M.V. Connors M.A. Haines G.K. Koch A.E. Arthritis Res. 2002; 4: 201-208Crossref PubMed Scopus (101) Google Scholar) have recently demonstrated that Ang-1 mRNA and protein are expressed in the synovium of patients with rheumatoid arthritis (RA). Ang-1 is expressed at low levels in primary human synovial fibroblasts obtained from patients with RA, and can be markedly up-regulated in response to inflammatory cytokines such as TNF-α. However, the transcriptional mechanisms by which Ang-1 gene expression is regulated are currently unknown.The purpose of this study was to begin to identify the molecular mechanisms of Ang-1 gene regulation in the setting of inflammation. Our findings support a central role for the ETS transcription factor ESE-1 during this process. ESE-1 was originally identified as a transcription factor that, under basal conditions, is highly restricted to cells of epithelial origin (13Oettgen P. Alani R.M. Barcinski M.A. Brown L. Akbarali Y. Boltax J. Kunsch C. Munger K. Libermann T.A. Mol. Cell. Biol. 1997; 17: 4419-4433Crossref PubMed Scopus (198) Google Scholar). However, in response to inflammatory stimuli, this factor can be induced in a variety of non-epithelial cells, including vascular smooth muscle cells, chondrocytes, synovial fibroblasts, and endothelial cells (14Rudders S. Gaspar J. Madore R. Voland C. Grall F. Patel A. Pellacani A. Perrella M.A. Libermann T.A. Oettgen P. J. Biol. Chem. 2001; 276: 3302-3309Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar, 15Grall F. Gu X. Tan L. Cho J.Y. Inan M.S. Pettit A.R. Thamrongsak U. Choy B.K. Manning C. Akbarali Y. Zerbini L. Rudders S. Goldring S.R. Gravallese E.M. Oettgen P. Goldring M.B. Libermann T.A. Arthritis Rheum. 2003; 48: 1249-1260Crossref PubMed Scopus (88) Google Scholar). We recently demonstrated that ESE-1 is highly expressed in the synovium of patients with rheumatoid arthritis (15Grall F. Gu X. Tan L. Cho J.Y. Inan M.S. Pettit A.R. Thamrongsak U. Choy B.K. Manning C. Akbarali Y. Zerbini L. Rudders S. Goldring S.R. Gravallese E.M. Oettgen P. Goldring M.B. Libermann T.A. Arthritis Rheum. 2003; 48: 1249-1260Crossref PubMed Scopus (88) Google Scholar). In this study we present direct evidence indicating a role for ESE-1 in Ang-1 gene regulation. ESE-1 can bind to specific ETS sites within the Ang-1 promoter that are functionally important for the transactivation by ESE-1, expression of ESE-1 in cultured cells leads to induction of the endogenous Ang-1 gene, and Ang-1 exhibits a similar and strong expression pattern in the synovium of patients with RA. In summary, our results support a role for the ETS factor ESE-1 as a novel transcriptional regulator of Ang-1 gene regulation in the setting of inflammation.EXPERIMENTAL PROCEDURESTissue Culture and Reagents—The cell lines HEK293 (human embryonic kidney), NIH3T3 (mouse fibroblast), and MCF-7 (human breast cancer) were grown in DMEM supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT) and antibiotics (penicillin and streptomycin; Invitrogen). Synovial tissue and bone were obtained at the time of arthroplasty or joint replacement surgery from patients with the clinical diagnosis of RA. Tissue procurement was approved by the Institutional Review Board. Dispersed synovial tissues were prepared by a previously published method (16Gravallese E.M. Manning C. Tsay A. Naito A. Pan C. Amento E. Goldring S.R. Arthritis Rheum. 2000; 43: 250-258Crossref PubMed Scopus (615) Google Scholar). Briefly, synovial tissues were minced on tissue culture plates and treated with Type I collagenase (4 mg/ml; Worthington Biochemical Corporation, Lakewood, NJ), in DMEM (Invitrogen), incubated for 1 h at 37 °C, treated with 0.25% trypsin for 30 min, harvested, and centrifuged at 1,000 rpm for 10 min. Pellets were suspended in 0.05% trypsin-0.02% EDTA, centrifuged, and resuspended in 50% phosphate-buffered saline (Ca2+/Mg2+-free), 50% DMEM containing 10% FCS (Sigma). Cells were then centrifuged and suspended in DMEM, 10% FCS, and plated at a density of 10 × 106 cells/10-cm plate. Cells were initially grown for 7–10 days and subsequently subjected to 2–4 passages. TNF-α and interleukin-1β (IL-1β) were purchased from R&D Systems (Minneapolis, MN).Expression Vector and Luciferase Reporter Gene Constructs—3239-, 1998-, and 1020-bp fragments corresponding to nucleotides -3040 to +199, -1799 to +199, and -821 to +199 of the human Ang-1 promoter were cloned from human genomic DNA (Clontech, Palo Alto, CA) by PCR and subcloned into the pGL2 luciferase reporter vector (Promega, Madison, WI). The 1998- and 1020-bp fragments were inserted into the XhoI-HindIII site and the 3239-bp fragment was inserted into the HindIII site upstream of the luciferase gene of the pGL2 vector.DNA Transfection Assays—Cotransfections of 2 × 105 HEK293 or NIH3T3 cells were carried out with varying amounts of reporter gene construct DNA and expression vector DNA using 4 μl of LipofectAMINE (Invitrogen) as described (17Oettgen P. Akbarali Y. Boltax J. Best J. Kunsch C. Libermann T.A. Mol. Cell. Biol. 1996; 16: 5091-5106Crossref PubMed Scopus (72) Google Scholar). The cells were harvested 16 h after transfection and assayed for luciferase activity. Transfections for every construct were performed independently in duplicates. Cotransfection of a second plasmid for determination of transfection efficiency was omitted because potential artifacts with this technique have been reported and because many commonly used viral promoters contain potential binding sites for ETS factors (18Farr A. Roman A. Nucleic Acids Res. 1992; 20: 920Crossref PubMed Scopus (115) Google Scholar).Site-directed Mutagenesis—Site-directed mutagenesis of the Ang-1 promoter was performed using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's recommendations. In brief, PCR primers encoding the Ang-1 promoter ETS site, -1565 to -1562, and flanking sequences were used, with ATAT substituted for ATCC: 5′-TGTGAATTACATATTGTTAGCCTT-3′ and 3′-AAGGCTAACAATATGTAATTCACA-5′. PCR was performed with Turbo polymerase using the wild type Ang-1 promoter fragment C luciferase reporter construct as a template. The PCR reaction was digested with DpnI, and the undigested plasmids were transformed into DH5α bacteria. Individual minipreps were sequenced to verify incorporation of the ETS site mutation.Electrophoretic Mobility Shift Assay—These were performed as described previously (19Dube A. Akbarali Y. Sato T.N. Libermann T.A. Oettgen P. Circ. Res. 1999; 84: 1177-1185Crossref PubMed Scopus (92) Google Scholar). In brief, whole cell extracts were made from primary human synovial fibroblasts after incubation with TNF-α or IL-1β for 0, 2, 6, 18, 24, and 48 h, using as lysis buffer 10% glycerol, 0.5% Nonidet P-40, 150 mm NaCl, 10 mm Tris pH 7.4, 1 mm phenylmethanesulfonyl fluoride, and 1 mm dithiothreitol. Whole cell extracts were obtained instead of nuclear extracts because the number of cells were limited and the primary synovial fibroblasts do not maintain their phenotype after 4–5 passages. 10 μg of whole cell extract or 2 μl of in vitro translation product and 0.1–0.2 ng of [32P]dATP-labeled double-stranded oligonucleotide probes (5,000–20,000 cpm) in the presence or absence of antibody were run on 4% polyacrylamide gels containing 0.5× TBE buffer. For supershift assays, 1 μl of rabbit polyclonal anti-ESE-1 antibody raised against a glutathione S-transferase fusion protein of the N terminus of human ESE-1 (East Acres Biologicals, Southbridge, MA) was used.Oligonucleotides used as probes are as follows (ETS consensus binding sites underlined: 1) human Ang-1 promoter site -2586 to -2567, 5′-TTTAATGCATCCTGAATTCT-3′ and 3′-AGAATTCAGGATGCATTAAA-5′; 2) human Ang-1 promoter site -2207 to -2188, 5′-TTCCCTCAGGAAATTGTGCA-3′ and 3′-TGCACAATTTCCTGAGGGAA-5′; 3) human Ang-1 promoter site -1573 to -1554, 5′-TGAATTACATCCTGTTAGCC-3′ and 3′-GGCTAACAGGATGTAATTCA-5′; 4) human Ang-1 promoter mutated site -1573 to -1554, 5′-GCTCTGTTGAATTACATATTGTTAGCCTTTC-3′ and 3′-GAAAGGCTAACAATATGTAATTCACAGAGC-5′.RT-PCR—Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNAs were generated from 2 μg of mRNA isolated from human synovial fibroblasts using oligo(dT)12–18 priming (Invitrogen) and Moloney murine leukemia virus-reverse transcriptase (Invitrogen). ESE-1, AML-1, and GAPDH RT-PCRs used equivalent amounts of 0.1 ng of cDNA, 4 ng/μl of each primer, 0.25 units of Taq polymerase (Promega), 150 μm of each dNTP, 3 mm of MgCl2, reaction buffer, and water to a final volume of 25 μl. Ang-1 RT-PCRs used equivalent amounts of 0.1 ng of cDNA, 4 ng/μl of each primer, 0.25 units of Advantage cDNA polymerase mix (Clontech), 150 μm of each dNTP, reaction buffer, and water to a final volume of 25 μl.The sequences of the primers used in this study are as follows: 1) Human ESE-1: sense, 5′-ACCTGGATCCCACTGATGGCAAGCTC-3′ and antisense, 5′-GGAGGAAGAGGTTCTCCAGAGTCGG-3′, with an expected amplification product of 457 bp. 2) Human Ang-1: sense, 5′-TTTCCTCGCTGCCATTCTGACTC-3′, and antisense, 5′-TATGGATGTCAATGGGGGAGGTT-3′, with an expected amplification product of 947bp. 3) Human AML-1: sense, 5′-AAGTCGCCACCTACCACAG-3′ and antisense, 5′-CTCAGCCTCAGAGTCAGATGC-3′, with an expected amplification product of 248 bp (21Niini T. Vettenranta K. Hollmen J. Larramendy M.L. Aalto Y. Wikman H. Nagy B. Seppanen J.K. Ferrer Salvador A. Mannila H. Saarinen-Pihkala U.M. Knuutila S. Leukemia. 2002; 16: 2213-2221Crossref PubMed Scopus (30) Google Scholar). 4) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH): sense, 5′-CAAAGTTGTCATGGATGACC-3′ and antisense, 5′-CCATGGAGAAGGCTGGGG-3′, with an expected amplification product of 200 bp.RT-PCR amplifications were carried out using a MJ Research thermal cycler PTC-100 as follows: ESE-1, 32 cycles of 30 s at 94 °C and 1 min 30 s at 68 °C followed by 7 min at 68 °C; Ang-1, 35 cycles of 30 s at 94 °C, and 1 min 30 s at 64 °C followed by 7 min at 64 °C; AML-1, 32 cycles of 30 s at 94 °C, 1 min at 60 °C, and 1 min 30 s at 72 °C followed by 10 min at 72 °C; GAPDH, 32 cycles of 30 s at 94 °C, 1 min at 56 °C, and 1 min 30 s at 72 °C followed by 10 min at 72 °C. 5 μl of the amplification product was analyzed on a 2% agarose gel.Western Blot Analysis—Whole cell lysates (50 μg) of MCF7 cells were boiled in Laemmli buffer and resolved on 10% SDS-PAGE acrylamide gel. Proteins were transferred on Hybond-polyvinylidene difluoride membranes and immunoblotted using the ECL Western blotting Detection reagents (Amersham Biosciences). Rabbit polyclonal anti-ESE-1 antibody raised against a glutathione S-transferase fusion protein of the N terminus of human ESE-1 (East Acres Biologicals, Southbridge, MA) was used at a dilution of 1:1,000, and revealed with an anti-rabbit horseradish peroxydase antibody (Cell Signaling Technology, Beverly, MA) at a dilution of 1:1,000.cDNA Microarrays—Microarray experiments were performed as previously described (22Gu X. Shin B.H. Akbarali Y. Weiss A. Boltax J. Oettgen P. Libermann T.A. J. Biol. Chem. 2001; 276: 9421-9436Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar). In brief, 1 × 106 human breast cancer MCF-7 cells were transiently transfected in duplicates with 8 μg of PCI-ESE-1 or PCI plasmid using the LipofectAMINE Plus system (Invitrogen). Total RNA was isolated separately from each plate 24 h after transfection using the RNeasy Kit (Qiagen) according to the manufacturer's instructions. Atlas Human Cancer 1.2 cDNA microarray nylon membranes (Clontech), each containing 1176 different genes, were hybridized with [32P]dATP-labeled cDNAs derived from 4 μg of total RNA according to the manufacturer at 68 °C in ExpressHyb solution (Clontech) using a Model 2000 Micro Hybridization Incubator (Robbins Scientific, Sunnyvale, CA). The filters were washed according to the user's instruction and exposed to Bio-Max MS film (Fisher) for different exposure times. Hybridizations were performed with duplicate experiments. The spot intensities reflecting gene expression levels on the Atlas human cDNA array were quantified using the Atlas Image 2.0 Software (Clontech). The transcriptional profiles in the cells overexpressing ESE-1 were compared with those in the cells transfected with parental PCI vector, normalizing spot intensities based on the average of the intensities of all spots. Genes up-regulated or down-regulated by ESE-1 were validated by RT-PCR.Immunohistochemistry—RA synovial soft tissue and bone were fixed for 48 h in 4% paraformaldehyde and specimens containing bone were subsequently decalcified for at least 2 weeks in 14% EDTA. Specimens were processed for paraffin embedding (Citadel 1000; Shandon, Pittsburgh, PA) and 4- or 5-μm serial sections were cut for immunohistochemical staining using an immunoperoxidase technique with diaminobenzidine (DAB; Dako, Carpinteria, CA) as the chromogen. Briefly, sections were deparaffinized followed by microwave antigen retrieval (GE Sensor convection microwave oven) in 10 mm EDTA pH 7.5 at 93 °C for 10 min and allowed to cool for at least 2 h. Sections were washed in Tris-buffered saline (TBS) and incubated for 60 min in serum block (10% fetal bovine serum and 10% normal rabbit serum diluted in TBS). Sections were then incubated with an affinity purified rabbit polyclonal anti-human Ang-1 antibody (L41309M, Regeneron Pharmaceuticals Inc., Tarrytown, NY), purified rabbit polyclonal anti-human ESE-1 antibody (AB3482, Chemicon International, Temecula, CA), or with an isotype matched control antibody (polyclonal Rabbit IgG, Santa Cruz Biotechnology Inc, Santa Cruz, CA) for 60 min. All incubations were carried out at room temperature. Sections were washed between every subsequent step with TBS. Endogenous peroxidase activity was blocked by incubating the sections in 3% H2O2 (diluted in TBS) for 30 min. Sections were subsequently incubated for 30 min with a biotinylated F(ab′)2 fragment of swine anti-rabbit immunoglobulin (Dako), followed by horseradish peroxidase-conjugated streptavidin (Dako), and developed with DAB (Dako) chromogen to the manufacturer's specifications. The sections were counterstained with hematoxylin (Sigma Diagnostics). Slides were examined and photographed using a transmitted light microscope and camera (Zeiss, Oberkochen, Germany).RESULTSIsolation and Characterization of the Human Ang-1 Promoter— The molecular mechanisms required for the induction of Ang-1 in response to inflammatory cytokines are currently unknown. To begin to identify potential mechanisms of Ang-1 gene regulation we isolated a series of genomic fragments (Fig. 1, A–C) of the human Ang-1 promoter, up to 3.2 kb in length, by long range PCR using human genomic DNA. The entire sequence of the Ang-1 gene is published in the human genome data base (accession NT 008046). Verification of the sequence was performed by automated sequencing. Comparison of the mouse and human Ang-1 promoter sequences revealed a relatively high overall degree of sequence homology. We examined the human Ang-1 promoter sequence for potential binding sites for transcription factors known to be involved in inflammation, such as NF-κB, JAK/STAT, PPAR, NFAT, and C/EBP. Surprisingly, no obvious binding site for any of these transcription factor families was identified. However, putative binding sites for members of the AP-1 and ETS families were identified. In addition, putative AML-1 and CBF-β binding sites were identified in the Ang-1 promoter.Induction of the Ang-1 Promoter by Inflammatory Cytokines—To evaluate whether the Ang-1 promoter contains regulatory elements capable of mediating induction in response to inflammatory cytokines the three genomic fragments encoding the Ang-1 promoter (A–C) were incorporated into the pGL2 luciferase reporter construct. NIH3T3 fibroblasts were transiently transfected with each Ang-1 reporter construct, followed by stimulation with TNF-α (Fig. 2A). We have previously demonstrated that TNF-α consistently induces Ang-1 mRNA expression in cultured synovial fibroblasts (10Gravallese E.M. Pettit A.R. Lee R. Madore R. Manning C. Tsay A. Gaspar J. Goldring M.B. Goldring S.R. Oettgen P. Ann. Rheum. Dis. 2003; 62: 100-107Crossref PubMed Scopus (80) Google Scholar). Stimulation of the 3.2-kb Ang-1 promoter construct C (-3040/+199) with TNF-α resulted in a 4-fold induction of the promoter. Similarly, stimulation of the 2-kb construct B (-1799/+199) with TNF-α led to a 4-fold increase in transactivation. However, further deletion to a 1-kb construct (Ang-1 A, -821/+199) markedly reduced the inducibility of the promoter to TNF-α, suggesting that the main regulatory elements responsible for mediating induction of the Ang-1 gene reside in the nucleotide region between -1799 and -821. We also examined the inducibility of constructs A and B in NIH3T3 fibroblasts after stimulation with IL-1β and LPS (Fig. 2, B and C). A 4–5-fold level of induction of the activity of construct B was seen in response to IL-1β and LPS, but no induction was seen with construct A, suggesting the importance of regulatory elements between nucleotides -1799 and -821 in mediating this induction of Ang-1 gene expression. This region contains putative AP-1 and ETS binding sites (Fig. 1).Fig. 2Transactivation of the Ang-1 promoter in response to inflammatory stimuli. Transactivation studies of Ang-1 luciferase reporter constructs A (-821/+199), B (-1799/+199), and C (-3040/+199) (300 ng each) in NIH3T3 fibroblasts after stimulation with TNF-α (50 ng/ml) (A), IL-1β (1 ng/ml) (B), or LPS (1 ng/ml) (C). The change in luciferase activity of the promoter construct after stimulation is expressed as fold induction compared with the activity of the promoter construct in unstimulated cells (DMEM supplemented with 10% FCS).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Transactivation of the Ang-1 Promoter by ETS Factors—As shown in Fig. 1, there are several putative binding sites for members of the ETS transcription factor family in the Ang-1 promoter. Selected members of the ETS transcription factor family have been shown previously to mediate the induction of other genes associated with inflammatory responses (23Wasylyk B. Hahn S.L. Giovane A. Eur. J. Biochem. 1993; 211: 7-18Crossref PubMed Scopus (809) Google Scholar, 24Kramer B. Wiegmann K. Kronke M. J. Biol. Chem. 1995; 270: 6577-6583Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). We therefore postulated that ETS factors might also be involved in the regulation of Ang-1 in response to inflammatory stimuli and tested the ability of a panel of ETS factors to transactivate the full-length Ang-1 promoter. Cotransfection experiments using mammalian expression plasmids encoding a panel of ETS factors and the 3.2-kb Ang-1 promoter luciferase construct were performed in HEK293 cells. We chose HEK293 cells because they do not express Ang-1 and can be transfected with high efficiency. As is shown in Fig. 3, only one of the ETS factors tested, ESE-1, was able to transactivate the Ang-1 promoter by ∼3-fold. These results suggest that ESE-1 is a potential transcriptional regulator of the Ang-1 promoter.Fig. 3Transactivation of the Ang-1 promoter by a panel of ETS factors. Transactivation of the 3.2-kb Ang-1 luciferase reporter construct C (-3040/+199) (300 ng) by a panel of ETS transcription factors (150 ng each) compared with the empty mammalian expression plasmid (PCI, 150 ng) in HEK293 cells. The change in luciferase activity is expressed as fold induction compared with PCI.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Binding of ESE-1 to Putative ETS Binding Sites—To further define the potential role of ESE-1 in the regulation of Ang-1, we evaluated the ability of ESE-1 to bind to putative ETS binding sites identified in the Ang-1 promoter by performing gel mobility shift assays. Three putative ETS binding sites were identified in the Ang-1 promoter corresponding to regions beginning at -2578, -2199, and -1565 (Fig. 1). The binding of in vitro translated ESE-1 protein was compared with control extracts in a gel mobility shift assay using radiolabeled oligonucleotides encoding the three putative ETS binding sites (Fig. 4). Whereas weak binding of ESE-1 to the first two sites (lanes 2 and 4) compared with the control extract (lanes 1 and 3) was observed, ESE-1 bound with high affinity to the third site (lane 6). Interestingly, this high affinity ESE-1 binding site (-1565/-1562) is located within the region of the Ang-1 promoter that is required for induction by inflammatory cytokines, whereas the low affinity sites are not.Fig. 4Gel mobility shift assays for ESE-1 binding to putative ETS sites in the Ang-1 promoter. In vitro translated ESE-1 protein (lanes 2, 4, 6) or control extract (lanes 1, 3, 5) was used with end-labeled oligonucleotide probes encoding putative ETS sites starting at positions -2578 (lanes 1 and 2), -2199 (lanes 3 and 4), and -1565
What problem does this paper attempt to address?
-
Ang-1 and VEGF: central regulators of angiogenesis
Jiang, Zhisheng
DOI: https://doi.org/10.1007/s11010-024-05010-3
IF: 3.842
2024-04-24
Molecular and Cellular Biochemistry
Abstract:Angiopoietin-1 (Ang-1) and Vascular Endothelial Growth Factor (VEGF) are central regulators of angiogenesis and are often inactivated in various cardiovascular diseases. VEGF forms complexes with ETS transcription factor family and exerts its action by downregulating multiple genes. Among the target genes of the VEGF-ETS complex, there are a significant number encoding key angiogenic regulators. Phosphorylation of the VEGF-ETS complex releases transcriptional repression on these angiogenic regulators, thereby promoting their expression. Ang-1 interacts with TEK, and this phosphorylation release can be modulated by the Ang-1-TEK signaling pathway. The Ang-1-TEK pathway participates in the transcriptional activation of VEGF genes. In summary, these elements constitute the Ang-1-TEK-VEGF signaling pathway. Additionally, Ang-1 is activated under hypoxic and inflammatory conditions, leading to an upregulation in the expression of TEK. Elevated TEK levels result in the formation of the VEGF-ETS complex, which, in turn, downregulates the expression of numerous angiogenic genes. Hence, the Ang-1-dependent transcriptional repression is indirect. Reduced expression of many target genes can lead to aberrant angiogenesis. A significant overlap exists between the target genes regulated by Ang-1-TEK-VEGF and those under the control of the Ang-1-TEK-TSP-1 signaling pathway. Mechanistically, this can be explained by the replacement of the VEGF-ETS complex with the TSP-1 transcriptional repression complex at the ETS sites on target gene promoters. Furthermore, VEGF possesses non-classical functions unrelated to ETS and DNA binding. Its supportive role in TSP-1 formation may be exerted through the VEGF-CRL5-VHL-HIF-1α-VH032-TGF-β-TSP-1 axis. This review assesses the regulatory mechanisms of the Ang-1-TEK-VEGF signaling pathway and explores its significant overlap with the Ang-1-TEK-TSP-1 signaling pathway.
cell biology
-
Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2
Wei Gao,Catherine Sweeney,Ceara Walsh,Peadar Rooney,Jennifer McCormick,Douglas J Veale,Ursula Fearon
DOI: https://doi.org/10.1136/annrheumdis-2012-201978
IF: 27.973
2012-11-17
Annals of the Rheumatic Diseases
Abstract:OBJECTIVE: Notch signalling pathways are critical for angiogenesis and endothelial cell (EC) fate; however the mechanisms regulating these processes in the inflamed joint remain to be elucidated. Here, we examine whether Notch signalling mediates vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2)-induced vascular function.METHODS: Notch-1 intracellular domain (Notch-1 IC), Notch-4 IC, Delta-like-ligand 4, Hes-related transcriptional repressors-1 and 2 (Hrt-1, Hrt-2) mRNA and/or protein expression was measured by Real-time PCR and/or western blot. VEGF/Ang2 induced EC function was assessed using transwell invasion chambers, matrigel tube formation assays and wound repair scratch assays±Notch-1 siRNA or an γ-secretase inhibitor N-(N-(3,5-Difluorophenacetyl-L-alanly))-S-phenylglycine-t-Butyl Ester (DAPT) in RA synovial explants or human microvascular EC. Interleukin (IL)-6 and IL-8 were measured by ELISA and MMP2 and 9 by gelatine zymography.RESULTS: Notch-1 IC and Notch-4 IC protein expressions were demonstrated in RA and psoriatic arthritis synovial biopsies, with minimal expression observed in Osteoarthritis (OA). VEGF and Ang2 induced Notch-1 IC/ Notch-4 IC protein expression in synovial explant cultures and human microvascular EC levels were further potentiated by VEGF/Ang2 stimulation in combination. Notch-1, Delta-like-ligand 4, and Hrt-2 mRNA expression were significantly induced by VEGF and Ang2 alone and in combination. Furthermore VEGF/Ang2-induced EC invasion, angiogenesis and migration were inhibited by Notch-1 siRNA or DAPT. Conditioned media from VEGF/Ang2 stimulated RA synovial explants induced EC tube formation, an effect that was inhibited by DAPT. Finally, DAPT significantly decreased VEGF/Ang2 induced IL-6, IL-8, MMP2 and 9 expressions in RA synovial explants.CONCLUSIONS: Notch-1 mediates VEGF/Ang2-induced angiogenesis and EC invasion in inflammatory arthritis.
rheumatology
-
Transcription Factor Ap-1 Mediates Proangiogenic MIF Expression in Human Endothelial Cells Exposed to Angiotensin II
Zhi-Xin Shan,Qiu-Xiong Lin,Min Yang,Bin Zhang,Jie-Ning Zhu,Li-Ping Mai,Chun-Yu Deng,Ju-Li Liu,You-Yi Zhang,Shu-Guang Lin,Xi-Yong Yu
DOI: https://doi.org/10.1016/j.cyto.2010.09.009
IF: 3.926
2011-01-01
Cytokine
Abstract:Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine associated with the atherosclerotic process and atherosclerotic plaque stability. MIF was shown to be highly expressed in advanced atherosclerotic lesions. Neutralizing MIF with a blocking antibody induced a regression of established atherosclerotic lesions. In this study, we investigated the mechanism underlying the proangiogenic effect of MIF in human umbilical vein endothelial cells (HUVECs). We showed that MIF induced the expression of angiogenesis-related genes in HUVECs. We also showed that MIF induced tube formation of HUVECs in vitro and in vivo. Angiotensin II (Ang II) could specifically up-regulate MIF expression in HUVECs. Using a luciferase reporter assay, we demonstrated that the AP-1 response element in the 5'-UTR of the MIF gene played a role in Ang II-induced MIF expression. Small hairpin RNA (shRNA) targeting c-Jun, a component of AP-1, and the AP-1 inhibitor CHX both efficiently inhibited MIF expression. The consistent result of electrophoretic mobility shift assay (EMSA) showed that Ang II specifically increased AP-1 activation in HUVECs. Our results suggest that AP-1 mediates Ang II-induced MIF expression which contributes to atherosclerotic plaque destabilization in human endothelial cells.
-
Angiotensin-converting Enzyme Defines Matrikine-Regulated Inflammation and Fibrosis
Philip J. O'Reilly,Qiang Ding,Samia Akthar,Guoqiang Cai,Kristopher R. Genschmer,Dhiren F. Patel,Patricia L. Jackson,Liliana Viera,Mojtaba Roda,Morgan L. Locy,Ellen A. Bernstein,Clare M. Lloyd,Kenneth E. Bernstein,Robert J. Snelgrove,J. Edwin Blalock
DOI: https://doi.org/10.1172/jci.insight.91923
IF: 9.4958
2017-01-01
JCI Insight
Abstract:The neutrophil chemoattractant proline-glycine-proline (PGP) is generated from collagen by matrix metalloproteinase-8/9 (MMP-8/9) and prolyl endopeptidase (PE), and it is concomitantly degraded by extracellular leukotriene A4 hydrolase (LTA4H) to limit neutrophilia. Components of cigarette smoke can acetylate PGP, yielding a species (AcPGP) that is resistant to LTA4H-mediated degradation and can, thus, support a sustained neutrophilia. In this study, we sought to elucidate if an antiinflammatory system existed to degrade AcPGP that is analogous to the PGP-LTA4H axis. We demonstrate that AcPGP is degraded through a previously unidentified action of the enzyme angiotensin-converting enzyme (ACE). Pulmonary ACE is elevated during episodes of acute inflammation, as a consequence of enhanced vascular permeability, to ensure the efficient degradation of AcPGP. Conversely, we suggest that this pathway is aberrant in chronic obstructive pulmonary disease (COPD) enabling the accumulation of AcPGP. Consequently, we identify a potentially novel protective role for AcPGP in limiting pulmonary fibrosis and suggest the pathogenic function attributed to ACE in idiopathic pulmonary fibrosis (IPF) to be a consequence of overzealous AcPGP degradation. Thus, AcPGP seemingly has very divergent roles: it is pathogenic in its capacity to drive neutrophilic inflammation and matrix degradation in the context of COPD, but it is protective in its capacity to limit fibrosis in IPF.
-
ANGIOTENSIN II PROMOTES DIFFERENTIATION OF MOUSE EMBRYONIC STEM CELLS TO VASCULAR SMOOTH MUSCLE CELLS THROUGH PI3-KINASE SIGNALLING PATHWAY AND NF-kappa B
Xiaoye Zheng,Yutao Wu,Qishan Chen,Yijiang Zhou,Li Zhang,Jianhua Zhu
DOI: https://doi.org/10.1136/heartjnl-2012-302920a.30
IF: 5.7
2012-01-01
Heart
Abstract:Objectives Embryonic stem cells (ES cells), the pluripotent derivatives of inner cell mass of blastocysts, have the capacity for unlimited growth, self-renewal and differentiate into all types of mature tissue cells. Angiotensin II (Ang II), the most important effector peptide of the renin–angiotensin system, is also an angiogenesis factor. This study attempted to explore the potential impact of Ang II on ES cells differentiation and the underlying mechanisms. Methods Mouse embryonic stem cells (ES-D3) were plated on collagen IV-coated dishes/flasks in differentiation medium for 2, 4, 6, 8 days, and a panel of smooth muscle specific markers, including smooth muscle a-actin (SMA), calponin, SM22, mouth muscle myosin heavy chain (SM-MHC) were detected by qRT-PCR and western blot. When the 4-day predifferentiated ES cells were pretreated with different concentrations (10−10–10−6 mol/l) of Ang II for 48 h, the mRNA, protein expression and immunofluorescent staining of smooth muscle specific markers were also detected. Besides, the 4-day predifferentiated ES cells were pre-incubated with different inhibitors, such as Ang II type 1 (AT1) receptor antagonist losartan (25 µmol/l, 50 µmol/l), Ang II type 2 (AT2) receptor antagonist PD123319 (1 µmol/l, 10 µmol/l), NF-κB inhibitor BAY11-7082 (5 µmol/l) and phosphoinositide-3 kinase (PI3K) inhibitor LY294002 (10 µmol/l), and the related expression of smooth muscle specific markers and phosphor-Akt were detected by western blot. The SMA and SM22 promoter activity on different concentrations of Ang II (10−10–10−6 mol/l) were detected by Luciferase reporter assay, and transcription factors c-Jun, NF-κB p50, NF-κB p65 were accordingly analysed by qRT-PCR. Finally, the protein expression of two proinflammatory factors, TNF-a and c-fos during Ang II (10−9 mol/l) stimulation were detected by western blot. Results We have successfully induced the differentiation of ES cells into vascular smooth muscle cells (SMCs) on collagen IV, and a panel of SMC-specific genes was significantly and consistently upregulated. Interestingly, incubation of ES cells with Ang II further promote SMC differentiation from ES cells, which was abolished by prior treatment with Ang II type 1 (AT1) receptor antagonist losartan (p<0.01), but not Ang II type 2 (AT2) receptor antagonist PD123319 (p>0.05). Ang II can directly promote the smooth muscle specific markers expression at the transcription level, as revealed that Ang II increased SMA-reporter activity, with the discernable effect observed at 10−8 mol/l and 10−9 mol/l (p<0.05). Moreover, we found that, in parallel with SMC specific-markers induction, the expression levels of phosphor-Akt and NF-KappaB (NF-κB) p50 were up-regulated by Ang II, with the maximum stimulation observed at 10−9mol/l (p<0.01). Importantly, addition of phosphoinositide-3 kinase (PI3K) inhibitor LY294002 led to a marked inhibition of Ang II induced VSMC specific markers, phosphor-Akt and NF-κB p50 expression (p<0.01). Furthermore, NF-κB inhibitor BAY11-7082 can inhibit Ang II induced expression of SMC specific markers (p<0.01). However, the protein expression of two proinflammatory factors TNF-a and c-fos were not changed much (p>0.05). Conclusions Thus, we demonstrate for the first time that Ang II plays a promotive role in the stage of ES cells differentiation to SMCs through AT1 receptor. We further confirmed that PI3K/Akt signalling pathway and NF-κB plays a key role in this process. Besides, Ang II can directly promote the smooth muscle specific markers expression at the transcription level, through stimulating many transcription factors especially transcription factor NF-κB p50, which may has the close relationship with SMC differentiation. However, the physiological effect of Ang II was not related with inflammation.
-
Abstract 1854: the Regulation of Angiogenin Expression and the Genes Regulated by Angiogenin
Jinghao Sheng,Guo-Fu Hu,Zhengping Xu
DOI: https://doi.org/10.1158/1538-7445.am2016-1854
IF: 11.2
2016-01-01
Cancer Research
Abstract:Abstract Angiogenin (ANG) is first isolated and identified by its ability to stimulate the growth of blood vessels. As a member of the vertebrate-specific secreted ribonuclease (RNase) family, ANG is encoded by a single exon and is usually located in the middle of its family gene cluster. Particularly, ANG gene locus has a unique gene arrangement, featured by shared promoters and 5’-untranslated regions (5’-UTR) which direct two distinct exons enconding ANG and ribounclease 4 (RNASE4, the 4th member of RNase family) respectively. However, the gene structure and regulation of these genetic regions are largely unknown. Here, we have characterized the promoters, defined the transcription start site, and identified a unique mechanism of transcription regulation. We demonstrated that two Pol III elements within the promoter regulate ANG and RNASE4 expression in a position- and orientation-dependent manner. Moreover, an intragenic chromatin loop formed between the two CCCTC-binding factor (CTCF)-binding sites located in two introns flanking ANG coding exon, which preferentially enhances ANG transcription. These results suggest a multilayer transcriptional regulation of ANG and RNASE4 gene locus. The data also add more direct evidence to the notion that Pol III elements are able to directly influence Pol II gene transcription. Furthermore, our data indicate that a CTCF-dependent chromatin loop is able to differentially regulate transcription of genes that share the same promoters. On the other hand, the secreted ANG undergoes a receptor-mediated endocytosis from the cell surface to the nucleus and accumulates in the nucleoli. The nucleoli ANG can promote 47S pre-rRNA transcription by binding the ABE (Angiogenin Binding Element) and UCE (Upstream Core Element) region on the promoter of ribosomal DNA (rDNA), where ANG increases the number of actively transcribing rDNA and promotes the assembly of initiation complex by epigenetic activation through promoter methylation and histone modification. We have also shown that the surplus ANG in nucleus also related to mRNA transcription. ANG binds the first exon region of estrogen receptor-related receptor gamma (ERRγ) and inhibits the ERRγ expression. To screen and identify the mRNAs regulated by ANG at a genome-wide level, we carried out chromatin immunoprecipitation-chip assay (ChIP-on-chip) and found a total of 699 genes that may be regulated by ANG. These genes were significantly enriched to tumorigenesis, Wnt and TGF-beta pathways by the KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis. Based on the findings that ANG is able to remodel the histone modification through direct binding to the histone protein, we propose that ANG might act as a chromatin remodeling activator to regulate RNA transcription. However, there is still a long way to go before fully disclosing the roles and mechanisms of ANG in gene transcription. Citation Format: Jinghao Sheng, Guo-fu Hu, Zhengping Xu. The regulation of angiogenin expression and the genes regulated by angiogenin. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1854.
-
VEGF and Angiopoietins Promote Inflammatory Cell Recruitment and Mature Blood Vessel Formation in Murine Sponge/Matrigel Model
Tharsika Sinnathamby,Tae Yun Jin,Marie‐Élaine Clavet‐Lanthier,Cheolho Cheong,Martin G. Sirois,Marie-Élaine Clavet-Lanthier
DOI: https://doi.org/10.1002/jcb.24941
2014-11-11
Journal of Cellular Biochemistry
Abstract:A key feature in the induction of pathological angiogenesis is that inflammation precedes and accompanies the formation of neovessels as evidenced by increased vascular permeability and the recruitment of inflammatory cells. Previously, we and other groups have shown that selected growth factors, namely vascular endothelial growth factor (VEGF) and angiopoietins (Ang1 and Ang2) do not only promote angiogenesis, but can also induce inflammatory response. Herein, given a pro-inflammatory environment, we addressed the individual capacity of VEGF and angiopoietins to promote the formation of mature neovessels and to identify the different types of inflammatory cells accompanying the angiogenic process over time. Sterilized polyvinyl alcohol (PVA) sponges soaked in growth factor-depleted Matrigel mixed with PBS, VEGF, Ang1, or Ang2 (200 ng/200 µl) were subcutaneously inserted into anesthetized mice. Sponges were removed at day 4, 7, 14, or 21 post-procedure for histological, immunohistological (IHC), and flow cytometry analyses. As compared to PBS-treated sponges, the three growth factors promoted the recruitment of inflammatory cells, mainly neutrophils and macrophages, and to a lesser extent, T- and B-cells. In addition, they were more potent and more rapid in the recruitment of endothelial cells (ECs) and in the formation and maturation (ensheating of smooth muscle cells around ECs) of neovessels. Thus, the autocrine/paracrine interaction among the different inflammatory cells in combination with VEGF, Ang1, or Ang2 provides a suitable microenvironment for the formation and maturation of blood vessels.
cell biology,biochemistry & molecular biology
-
Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis
S. Fromm,C. C. Cunningham,M. R. Dunne,D. J. Veale,U. Fearon,S. M. Wade
DOI: https://doi.org/10.1186/s13075-019-2088-3
2019-12-01
Abstract:Abstract Introduction Angiogenesis is an early event in the pathogenesis of both psoriatic arthritis (PsA) and rheumatoid arthritis (RA); however, there are striking differences in blood vessel morphology and activation between the two arthropathies. The aim of this study was to assess if the PsA and RA joint microenvironments differentially regulate endothelial cell function. Methods PsA and RA primary synovial fibroblasts (SFC) were isolated from synovial biopsies, grown to confluence, and supernatants harvested and termed ‘conditioned media’ (CM). Human umbilical vein endothelial cells (HUVEC) were cultured with PsA SFC or RA SFC-CM (20%). HUVEC tube formation, migration, and PBMC adhesion were assessed by matrigel tube formation, wound repair, and PBMC adhesion assays. HUVEC cell surface expression of ICAM, VCAM, and E-Selectin was assessed by flow cytometry. Transcriptome analysis of genes promoting angiogenesis was performed by real-time PCR. Finally, a MSD multiplex angiogenic assay was performed on PsA SFC and RA SFC supernatants. Results Macroscopic synovitis and vascularity were similar in PsA and RA patients; however, significant differences in vascular morphological pattern were recorded with tortuous, elongated vessels observed in PsA compared to straight regular branching vessels observed in RA. Transcriptome analysis showed strong upregulation of the pro-angiogenic signature in HUVEC primed with PsA SFC-CM compared to RA SFC-CM and basal control. In parallel, paired PsA SFC-CM significantly induced HUVEC tube formation compared to that of RA SFC-CM. Furthermore, PsA SFC-CM induced HUVEC migration was paralleled by a significant induction in VEGFA, PFKFB3, ICAM-1, and MMP3 mRNA expression. A significant increase in PBMC adhesion and cell surface expression of VCAM-1, ICAM-1, and E-Selectin expression was also demonstrated in PsA SFC-CM-primed HUVEC compared to RA SFC-CM. Finally, VEGF, TSLP, Flt-1, and Tie-2 expression was elevated in PsA SFC-CM compared to RA SFC-CM, with no significant difference in other pro-angiogenic mediators including MIP-3, bFGF, PIGF, and MCP-1. Conclusion PsA SFC and RA SFC secreted factors differentially regulate endothelial cell function, with soluble mediators in the PsA joint microenvironment inducing a more pro-angiogenic phenotype compared to the RA.
rheumatology
-
Apelin Promotes Endothelial Progenitor Cell Angiogenesis in Rheumatoid Arthritis Disease via the miR-525-5p/Angiopoietin-1 Pathway
Ting-Kuo Chang,You-Han Zhong,Shan-Chi Liu,Chien-Chung Huang,Chun-Hao Tsai,Hsiang-Ping Lee,Shih-Wei Wang,Chin-Jung Hsu,Chih-Hsin Tang
DOI: https://doi.org/10.3389/fimmu.2021.737990
IF: 7.3
2021-09-29
Frontiers in Immunology
Abstract:Angiogenesis is a critical process in the formation of new capillaries and a key participant in rheumatoid arthritis (RA) pathogenesis. The adipokine apelin (APLN) plays critical roles in several cellular functions, including angiogenesis. We report that APLN treatment of RA synovial fibroblasts (RASFs) increased angiopoietin-1 (Ang1) expression. Ang1 antibody abolished endothelial progenitor cell (EPC) tube formation and migration in conditioned medium from APLN-treated RASFs. We also found significantly higher levels of APLN and Ang1 expression in synovial fluid from RA patients compared with those with osteoarthritis. APLN facilitated Ang1-dependent EPC angiogenesis by inhibiting miR-525-5p synthesis via phospholipase C gamma (PLCγ) and protein kinase C alpha (PKCα) signaling. Importantly, infection with APLN shRNA mitigated EPC angiogenesis, articular swelling, and cartilage erosion in ankle joints of mice with collagen-induced arthritis. APLN is therefore a novel therapeutic target for RA.
immunology
-
Inflammatory properties of inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis
Gautam Edhayan,Ray A Ohara,W Alex Stinson,M Asif Amin,Takeo Isozaki,Christine M Ha,G Kenneth Haines 3rd,Rachel Morgan,Phillip L Campbell,Ali S Arbab,Sean C Friday,David A Fox,Jeffrey H Ruth
DOI: https://doi.org/10.1186/s13075-016-0984-3
2016-04-12
Abstract:Background: Inhibitor of DNA binding 1 (Id1) is a nuclear protein containing a basic helix-loop-helix (bHLH) domain that regulates cell growth by selective binding and prevention of gene transcription. Sources of Id1 production in rheumatoid arthritis synovial tissue (RA ST) and its range of functional effects in RA remain to be clarified. Methods: We analyzed Id1 produced from synovial fibroblasts and endothelial cells (ECs) with histology and real-time polymerase chain reaction (RT-PCR). Fibroblast supernatants subjected to differential centrifugation to isolate and purify exosomes were measured for Id1 by enzyme-linked immunosorbent assay (ELISA). Western blotting of Id1-stimulated ECs was performed to determine the kinetics of intracellular protein phosphorylation. EC intracellular signaling pathways induced by Id1 were subsequently targeted with silencing RNA (siRNA) for angiogenesis inhibition. Results: By PCR and histologic analysis, we found that the primary source of Id1 in STs is from activated fibroblasts that correlate with inflammatory scores in human RA ST and in joints from K/BxN serum-induced mice. Normal (NL) and RA synovial fibroblasts increase Id1 production with stimulation by transforming growth factor beta (TGF-β). Most of the Id1 released by RA synovial fibroblasts is contained within exosomes. Endothelial progenitor cells (EPCs) and human dermal microvascular ECs (HMVECs) activate the Jnk signaling pathway in response to Id1, and Jnk siRNA reverses Id1-induced HMVEC vessel formation in Matrigel plugs in vivo. Conclusions: Id1 is a pleotropic molecule affecting angiogenesis, vasculogenesis, and fibrosis. Our data shows that Id1 is not only an important nuclear protein, but also can be released from fibroblasts via exosomes. The ability of extracellular Id1 to activate signaling pathways expands the role of Id1 in the orchestration of tissue inflammation.
-
Egr-1 target genes in human endothelial cells identified by microarray analysis.
Mingui Fu,Xiaojun Zhu,Jifeng Zhang,Jian Liang,Yiming Lin,Luning Zhao,Markus U Ehrengruber,Yuqing E Chen
DOI: https://doi.org/10.1016/S0378-1119(03)00730-3
IF: 3.913
2003-01-01
Gene
Abstract:Early growth response factor 1 (Egr-1) is a key transcriptional factor to mediate gene expression after vascular injury. To better understand the role of Egr-1 in vasculature, we globally profiled Egr-1 target genes in human endothelial cells using adenoviral gene transfer and Affymetrix oligonucleotide-based microarray technology. More than 300 genes regulated by ≥3-fold with Egr-1 overexpression were identified and, partially, confirmed by Northern and Western blotting, including genes for transcriptional regulators, signaling proteins, cell cycle regulatory proteins, growth factors, and cytokines. Among them, thymus-expressed chemokine (TECK) and IP-30 were dramatically induced by Egr-1, but TNFα-related apoptosis inducing ligand (TRAIL) was significantly repressed by Egr-1, suggesting that Egr-1 is a key mediator of inflammation and apoptosis in vascular cells. These data provide novel Egr-1 target genes and contribute to the understanding of the role of Egr-1 in vasculature.
-
Adiponectin Promotes VEGF Expression in Rheumatoid Arthritis Synovial Fibroblasts and Induces Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-106a-5p
Chien-Chung Huang,Yat-Yin Law,Shan-Chi Liu,Sung-Lin Hu,Jun-An Lin,Chao-Ju Chen,Shih-Wei Wang,Chih-Hsin Tang
DOI: https://doi.org/10.3390/cells10102627
IF: 6
2021-10-01
Cells
Abstract:Rheumatoid arthritis (RA) is an erosive polyarthritis that can lead to severe joint destruction and painful disability if left untreated. Angiogenesis, a critical pathogenic mechanism in RA, attracts inflammatory leukocytes into the synovium, which promotes production of proinflammatory cytokines and destructive proteases. Adipokines, inflammatory mediators secreted by adipose tissue, also contribute to the pathophysiology of RA. The most abundant serum adipokine is adiponectin, which demonstrates proinflammatory effects in RA, although the mechanisms linking adiponectin and angiogenic manifestations of RA are not well understood. Our investigations with the human MH7A synovial cell line have revealed that adiponectin dose- and time-dependently increases vascular endothelial growth factor (VEGF) expression, stimulating endothelial progenitor cell (EPC) tube formation and migration. These adiponectin-induced angiogenic activities were facilitated by MEK/ERK signaling. In vivo experiments confirmed adiponectin-induced downregulation of microRNA-106a-5p (miR-106a-5p). Inhibiting adiponectin reduced joint swelling, bone destruction, and angiogenic marker expression in collagen-induced arthritis (CIA) mice. Our evidence suggests that targeting adiponectin has therapeutic potential for patients with RA. Clinical investigations are needed.
cell biology
-
S1P Increases VEGF Production in Osteoblasts and Facilitates Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-16-5p Expression via the c-Src/FAK Signaling Pathway in Rheumatoid Arthritis
Chien-Chung Huang,Tzu-Ting Tseng,Shan-Chi Liu,Yen-You Lin,Yat-Yin Law,Sung-Lin Hu,Shih-Wei Wang,Chun-Hao Tsai,Chih-Hsin Tang
DOI: https://doi.org/10.3390/cells10082168
IF: 6
2021-08-23
Cells
Abstract:Angiogenesis is a critical process in the formation of new capillaries and a key participant in rheumatoid arthritis (RA) pathogenesis. Vascular endothelial growth factor (VEGF) stimulation of endothelial progenitor cells (EPCs) facilitates angiogenesis and the progression of RA. Phosphorylation of sphingosine kinase 1 (SphK1) produces sphingosine-1-phosphate (S1P), which increases inflammatory cytokine production, although the role of S1P in RA angiogenesis is unclear. In this study, we evaluated the impact of S1P treatment on VEGF-dependent angiogenesis in osteoblast-like cells (MG-63 cells) and the significance of SphK1 short hairpin RNA (shRNA) on S1P production in an in vivo model. We found significantly higher levels of S1P and VEGF expression in synovial fluid from RA patients compared with those with osteoarthritis by ELISA analysis. Treating MG-63 cells with S1P increased VEGF production, while focal adhesion kinase (FAK) and Src siRNAs and inhibitors decreased VEGF production in S1P-treated MG-63 cells. Conditioned medium from S1P-treated osteoblasts significantly increased EPC tube formation and migration by inhibiting miR-16-5p synthesis via proto-oncogene tyrosine-protein kinase src (c-Src) and FAK signaling in chick chorioallantoic membrane (CAM) and Matrigel plug assays. Infection with SphK1 shRNA reduced angiogenesis, articular swelling and cartilage erosion in the ankle joints of mice with collagen-induced arthritis (CIA). S1P appears to have therapeutic potential in RA treatment.
cell biology
-
AGGF1 is a novel anti-inflammatory factor associated with TNF-α-induced endothelial activation.
Fang-Yuan Hu,Chong Wu,Yang Li,Ke Xu,Wen-Jing Wang,Huiqing Cao,Xiao-Li Tian
DOI: https://doi.org/10.1016/j.cellsig.2013.04.007
IF: 4.85
2013-01-01
Cellular Signalling
Abstract:Endothelial activation contributes to the development of vascular inflammation and subsequent vascular diseases, particularly atherosclerosis. AGGF1, a new member of angiogenic factors with a FHA and a G-patch domain, has been shown critical for the regulation of vascular differentiation and angiogenesis. In this study, we found that various inflammatory cytokines strongly induced the expression of AGGF1 in endothelial cells (ECs) and identified AGGF1 as a novel anti-inflammatory factor both in vivo and in vitro. Overexpression of AGGF1 significantly repressed the expression of pro-inflammatory molecules such as E-Selectin, ICAM-1, and IL-8 and the adhesion of monocytes onto ECs activated by TNF-α. Conversely, the knockdown of AGGF1 resulted in the increased expressions of these pro-inflammatory molecules and the enhanced monocyte-EC interaction. We further demonstrated that AGGF1 potently attenuated TNF-α triggered NF-κB pathway, as indicated by the decreased promoter activity, nuclear distribution and phosphorylation of NF-κB p65 subunit as well as the increased protein level of IκBα. This inhibitory effect of AGGF1 was further proved through blocking the phosphorylation of ERK induced by TNF-α. Finally, we showed that the FHA domain of AGGF1 was required for its anti-inflammatory effect. Thus, our findings for the first time demonstrate that AGGF1 suppresses endothelial activation responses to TNF-α by antagonizing the ERK/NF-κB pathway, which makes AGGF1 a promising therapeutic candidate for the prevention and treatment of inflammatory diseases.
-
Angiotensin Ii Promotes Smooth Muscle Cell Proliferation and Migration Through Release of Heparin-Binding Epidermal Growth Factor and Activation of Egf-Receptor Pathway
XP Yang,MJ Zhu,N Sreejayan,J Ren,M Du
DOI: https://doi.org/10.1016/s1016-8478(23)13226-2
2005-01-01
Abstract:Transactivation of EGF-receptor (EGFR) by G-protein coupled receptors (GPCRs) is emerging as an important pathway in cell proliferation, which plays a crucial role in the development of atherosclerotic lesion. Angiotensin II (Ang II) has been identified to have a major role in the formation of atherosclerotic lesions, although the underlying mechanisms remain largely unclear. We hypothesize that Ang II promotes the proliferation and migration of smooth muscle cells through the release of heparin-binding epidermal growth factor like growth factor (HB-EGF), transactivation of EGFR and activation of Akt and Erk 1/2, with matrix metalloproteases (MMPs) playing a dispensable role. Primary rat aortic smooth muscle cells were used in this study. Smooth muscle cells rendered quiescent by serum deprivation for 12 h were treated with Ang II (100 mu m) in the presence of either GM6001 (20 mu M), a specific inhibitor of MMPs or AG1478 (10 mu M), an inhibitor of EGFR. The levels of phosphorylation of EGFR, Akt and Erk 1/2 were assessed in the cell lysates. Inhibition of MMPs by GM6001 significantly attenuated Ang II-stimulated phosphorylation of EGFR, suggesting that MMPs may be involved in the transactivation of EGFR by Ang II receptor. Furthermore Ang II-stimulated proliferation and migration of smooth muscle cells were significantly blunted by inhibiting MMPs and EGFR and applying HB-EGF neutralization antibody, indicating that MMPs, HB-EGF and EGFR activation is necessary for Ang-II stimulated migration and proliferation of smooth muscle cells. Our results suggest that inhibition of MMPs may represent one of the strategies to counter the mitogenic and motogenic effects of Ang II on smooth muscle cells and thereby prevent the formation and development of atherosclerotic lesions.
-
Abstract MP02: Angiotensin II Mediates Microvascular Rarefaction In Vivo and Exacerbates Endothelial-To-Mesenchymal Transition In Vitro
Katrin Nather,Mónica Flores-Muñoz,Rhian M Touyz,Christopher M Loughrey,Stuart A Nicklin
DOI: https://doi.org/10.1161/hyp.66.suppl_1.mp02
IF: 9.8968
2015-09-01
Hypertension
Abstract:Cardiac fibrosis accompanies numerous cardiovascular diseases (CVD) such as hypertension and myocardial infarction and increases myocardial stiffness leading to contractile dysfunction. Recently, endothelial-to-mesenchymal transition (EndMT) has been shown to contribute to myocardial fibrosis. EndMT describes a process by which endothelial cells transform into mesenchymal cells such as fibroblasts and has been implicated in many fibrotic diseases. Angiotensin II (AngII) plays a key role in myocardial fibrosis and has been associated with the activation of fibroblasts to myofibroblasts and an increase in myocardial collagen deposition. Here, we assessed the role of AngII in capillary loss and EndMT in vivo and in vitro . C57BL/6J mice were infused with H 2 O (control) or 24μg/kg/hr AngII for 4 weeks. Mice infused with AngII developed significant cardiac fibrosis characterised by the deposition of collagen I (2.5-fold vs. control; p<0.05) and III (1.9-fold vs. control; p<0.05). Capillary density was assessed by CD31 immunohistochemistry and revealed significant vascular rarefaction (control 2161±111 vs . AngII 838±132 capillaries/mm 2 ; p<0.05). To investigate whether AngII can induce EndMT in vitro , human coronary artery endothelial cells were stimulated with 10ng/mL TGFβ 1 alone or in combination with 1μM AngII for 10 days. AngII significantly enhanced TGFβ 1 -induced gene expression of α-smooth muscle actin (TGFβ 1 1.8-fold; TGFβ 1 ±AngII 4.3-fold vs . control; p<0.05) and collagen I (TGFβ 1 9.2-fold; TGFβ 1 +AngII 30.2-fold vs . control; p<0.05). Concomitantly, AngII significantly increased α-smooth muscle actin protein expression (TGFβ 1 3.9-fold; TGFβ 1 +AngII 23.6-fold vs . control; p<0.05) and significantly decreased CD31 expression (TGFβ 1 0.9-fold; TGFβ 1 +AngII 0.7-fold vs . control; p<0.05), suggesting AngII acts in concert with TGFβ 1 to enhance conversion of endothelial cells to myofibroblasts. Further studies investigating the underlying mechanism, including the role of the Smad pathway, are ongoing. These results demonstrate that AngII induces vascular rarefaction in vivo and potentiates TGFβ 1 -induced EndMT in vitro. Understanding the molecular basis for these observations may help to identify new therapeutic options in CVD.
peripheral vascular disease
-
Data from Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment
Tanja Holopainen,Huilian Huang,Caiping Chen,Kyung Eun Kim,Luqing Zhang,Fei Zhou,Wencan Han,Chaojun Li,Jun Yu,Jun Wu,Gou Young Koh,Kari Alitalo,Yulong He
DOI: https://doi.org/10.1158/0008-5472.c.6499239
2023-01-01
Abstract:AbstractThe angiopoietin-1 (Ang1)/Tie2 signaling pathway is known to play an important role in the regulation of vascular maturation and maintenance of vessel integrity. In this study, we have investigated the effect of systemic Tie2 activation or inhibition on tumor growth and metastasis. We found that treatment with Ang1 delivered via an adenoviral vector promoted s.c. implanted tumor metastasis to the lungs. Ang1 treatment did not significantly increase vascular density in the tumors but induced enlargement of blood vessels in both the tumor and normal tissues, which increased tumor cell dissemination into the blood circulation. Ang1 also enhanced the formation of metastatic foci in the lungs when tumor cells were injected into the circulation via the tail vein. The effect of Ang1 on metastasis was validated by a simultaneous treatment with a soluble form of Tie2 (sTie2), which led to the suppression of Ang1-induced increase of tumor metastasis. Furthermore, using a highly metastatic tumor model, we confirmed that systemic treatment with sTie2 suppressed tumor metastasis to the lungs and lymph nodes, whereas tumor-associated angiogenesis and lymphangiogenesis were not significantly affected. This suggests that the Ang1/Tie2 signals contribute to tumor progression by increasing vascular entry and exit of tumor cells to facilitate tumor dissemination and establishment of metastases. [Cancer Res 2009;69(11):4656–64]
-
Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA
Helene Larsen,Barbara Muz,Tak L Khong,Marc Feldmann,Ewa M Paleolog
DOI: https://doi.org/10.1186/ar3934
2012-01-01
Abstract:IntroductionHypoxia and T-helper cell 1 (Th1) cytokine-driven inflammation are key features of rheumatoid arthritis (RA) and contribute to disease pathogenesis by promoting angiogenesis. The objective of our study was to characterise the angiogenic gene signature of RA fibroblast-like synoviocytes (FLS) in response to hypoxia, as well as Th1 and T-helper cell 2 (Th2) cytokines, and in particular to dissect out effects of combined hypoxia and cytokines on hypoxia inducible transcription factors (HIFs) and angiogenesis.MethodsHuman angiogenesis PCR arrays were used to screen cDNA from RA FLS exposed to hypoxia (1% oxygen) or dimethyloxalylglycine, which stabilises HIFs. The involvement of HIF isoforms in generating the angiogenic signature of RA FLS stimulated with hypoxia and/or cytokines was investigated using a DNA-binding assay and RNA interference. The angiogenic potential of conditioned media from hypoxia-treated and/or cytokine-treated RA FLS was measured using an in vitro endothelial-based assay.ResultsExpression of 12 angiogenic genes was significantly altered in RA FLS exposed to hypoxia, and seven of these were changed by dimethyloxalylglycine, including ephrin A3 (EFNA3), vascular endothelial growth factor (VEGF), adipokines angiopoietin-like (ANGPTL)-4 and leptin. These four proangiogenic genes were dependent on HIF-1 in hypoxia to various degrees: EFNA3 >ANGPTL-4 >VEGF >leptin. The Th1 cytokines TNFα and IL-1β induced HIF-1 but not HIF-2 transcription as well as activity, and this effect was additive with hypoxia. In contrast, Th2 cytokines had no effect on HIFs. IL-1β synergised with hypoxia to upregulate EFNA3 and VEGF in a HIF-1-dependent fashion but, despite strongly inducing HIF-1, TNFα suppressed adipokine expression and had minimal effect on EFNA3. Supernatants from RA FLS subjected to hypoxia and TNFα induced fewer endothelial tubules than those from FLS subjected to TNFα or hypoxia alone, despite high VEGF protein levels. The Th2 cytokine IL-4 strongly induced ANGPTL-4 and angiogenesis by normoxic FLS and synergised with hypoxia to induce further proangiogenic activity.ConclusionThe present work demonstrates that Th1 cytokines in combination with hypoxia are not sufficient to induce angiogenic activity by RA FLS despite HIF-1 activation and VEGF production. In contrast, Th2 cytokines induce angiogenic activity in normoxia and hypoxia, despite their inability to activate HIFs, highlighting the complex relationships between hypoxia, angiogenesis and inflammation in RA.
rheumatology
-
Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblasts
B. Liu,J. Yu,L. Taylor,X. Zhou,P. Polgar
DOI: https://doi.org/10.1002/jcb.20709
2006-01-01
Journal of Cellular Biochemistry
Abstract:Rat1 fibroblasts stably transfected with the rat angiotensin II (AngII) AT1a and bradykinin (BK) B2 receptor cDNAs gained the ability to bind Ang II and BK. Wild-type Rat1 cells bound neither ligand. Exposure to either effector led to characteristic Galphai and Galphaq signal cascades, the release of arachidonic acid (ARA), and the intracellular accumulation of inositol phosphates (IP). Microarray analyses in response to BK or AngII showed that both receptors markedly induce the CCN family genes, CTGF (CCN2) and Cyr61 (CCN1), as well as the vasculature-related genes, Cnn1 and Egr1. Real time PCR confirmed the increased expression of connective tissue growth factor (CTGF) mRNA. Combined sequence-based analysis of gene promoter regions with statistical prevalence analyses identified CREB, SRF, and ATF-1, downstream targets of ERK, and JNK, as prominent products of genes that are regulated by ligand binding to the BK or AngII receptors. The binding of AngII or BK markedly stimulated the phosphorylation and thus the activation of ERK2, JNK, and p38MAPK. A BKB2R and an AT1aR chimera which displayed only negligible G-protein-related signaling were constructed. Both mutant receptors continued to activate these kinases and stimulate CTGF expression. Inhibitors of ERK1/2 and JNK but not p38MAPK inhibited the BK- and AngII-stimulated expression of CTGF in cells expressing either the WT or mutant receptors, illustrating that ERK and JNK participate in the control of CTGF expression in a manner that appears to be independent of G-protein. Conversely, addition of BK or AngII to the cell line expressing WT AT1aR and BKB2R downregulated the expression of collagen alpha1(I) (COL1A1) mRNA. However, these effectors did not have this effect in cells expressing the mutant receptors. Thus, a robust G-protein related response is necessary for BK or AngII to affect COL1A1 expression.
cell biology,biochemistry & molecular biology
-
Endothelial Intracellular ANG (Angiogenin) Protects Against Atherosclerosis by Decreasing Endoplasmic Reticulum Stress
Enyong Su,Peng Yu,Baoli Zhang,Anjing Zhang,Shiyao Xie,Chunyu Zhang,Su Li,Yunzeng Zou,Ming Liu,Hong Jiang,Junbo Ge
DOI: https://doi.org/10.1161/ATVBAHA.121.317339
2022-01-22
Abstract:ANG (angiogenin) is essential for cellular adaptation to endoplasmic reticulum (ER) stress, a process closely associated with cardiovascular diseases, including atherosclerosis. We aimed to investigate the role of ANG in the progression of atherosclerosis and elucidate its underlying molecular mechanisms. We constructed adenoassociated virus 9 ANG overexpression vectors and endothelial ANG- and ApoE (apolipoprotein E)-deficient mice to determine the effects of ANG on ER stress and atherosclerotic lesions. RNA sequencing of endothelial ANG- and ApoE-deficient mice identified ANG-dependent downregulation of ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) expression, and the direct regulation of ST3GAL5 by ANG was verified by chromatin immunoprecipitation sequencing and luciferase reporter assay results. Reanalysis of expression profiling datasets indicated decreased ANG levels in patients' atherosclerotic lesions, and these data were validated in aortas from ApoE − /− mice. ER stress marker and adhesion molecule levels, aortic root lesions and macrophage deposition were substantially reduced in ApoE −/− mice injected with an adenoassociated virus 9 ANG without signal peptide (ANG-ΔSP) overexpression vector compared with empty and full-length ANG overexpression vectors. Endothelial ANG deficiency significantly elevated ER stress and increased adhesion molecule expression, which aggravated atherosclerotic lesions and enhanced THP-1 monocyte adhesion to endothelial cells in vivo and in vitro, respectively. Furthermore, ANG-ΔSP overexpression significantly attenuated oxidized low-density lipoprotein-induced ER stress and THP-1 monocyte adhesion to endothelial cells, which were reversed by ST3GAL5 inhibition. These results suggest that endothelial intracellular ANG is a novel therapeutic against atherosclerosis and exerts atheroprotective effects via ST3GAL5-mediated ER stress suppression.